Four cases of hyperparathyroidism-jaw tumor syndrome in young patients with primary hyperparathyroidism in Russia

E. Mamedova, N. Mokrysheva, E. Pigarova, I. Voronkova, E. Vasilyev, V. Petrov, L. Rozhinskaya, A. Tiulpakov

Endocrinology Research Center, Moscow, Russia

Introduction: Hyperparathyroidism-jaw tumor (HPT-JT) syndrome is a rare autosomal-dominant disorder caused by mutations in CDC73 tumor suppressor gene. To date about 80 mutations in CDC73 have been described. Four patients among a cohort of young patients (<40 y.o.) with primary hyperparathyroidism (PHPT) underwent next-generation sequencing (NGS) (Ion Torrent™ PGM™, Thermo Fisher Scientific-Life Technologies, USA) using a custom-designed Ion AmpliSeq™ gene panel.

Case 1. A female with PHPT manifestation at age 20, osteitis fibrosa cystica (OFC), kidney microlithiasis, serum Ca 4.09 mmol/l (2.15-2.55), parathyroid hormone (PTH) 2440 pg/ml (15-65) due to parathyroid carcinoma, and endometrial polyp at diagnosis. At age 26 her PHPT recurred as lung metastases of parathyroid carcinoma, requiring surgical intervention. NGS revealed a novel nonsense mutation in exon 3 p.R91X.

Case 2. A female with PHPT manifestation at age 24, severe OFC, kidney microlithiasis, serum Ca 3.36 mmol/l, Ca²⁺ 1.56 mmol/l (1.03-1.29), PTH 558.8 pg/ml due to parathyroid carcinoma. A patient had positive family history, with polycystic kidney disease in her mother. NGS revealed a nonsense mutation in exon 6 p.Q166X.

Case 3. A male with PHPT manifestation at age 22, severe OFC, serum Ca 3.9 mmol/l, Ca²⁺ 1.84 mmol/l, PTH 1441 pg/ml due to parathyroid carcinoma. NGS revealed a novel nonsense mutation in exon 7 p.R229X.

Case 4. A female with mild PHPT manifestation at age 30, serum Ca 2.94 mmol/l, Ca²⁺ 1.24 mmol/l, PTH 125.1 pg/ml due to single parathyroid hyperplasia. NGS revealed a novel missense mutation in exon 8 p.R263C.

Vascular invasion, anti-CD31 antibodyx50

Parathyroid hyperplasia, H&Ex100

Conclusion: We describe four cases of HPT-JT syndrome in young patients with PHPT in Russia. 3 of 4 mutations are described for the first time. Occurrence of nonsense CDC73 mutations in patients with parathyroid carcinoma and a missense mutation in a patient with parathyroid hyperplasia may reflect various degrees of parafibromin dysfunction.

The reported study was funded by RFBR according to the research project (grant) № 16-34-00401 мол_а.